Octave Bioscience

Executive Summary

Octave Bioscience is a private neurodiagnostics company offering the Octave MSDA Test, the first multi-analyte blood test designed to monitor disease activity in multiple sclerosis (MS). Launched nationwide through Quest Diagnostics, the test measures 18 protein biomarkers to provide a comprehensive assessment of MS progression and treatment response, enabling personalized care. Founded in 2018 and based in Menlo Park, CA, Octave aims to transform MS management by replacing subjective clinical evaluations with objective molecular data. The company's platform has the potential to reduce relapses and healthcare costs by guiding therapy decisions early. With MS affecting nearly 1 million people in the U.S., Octave addresses a significant unmet need for reliable, non-invasive monitoring tools. The MSDA Test is currently available as a laboratory-developed test (LDT) under CLIA certification, positioning Octave to capture market share in the growing precision neurology space.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance of the MSDA Test as an in vitro diagnostic40% success
• Q2 2026Publication of prospective clinical validation data demonstrating improved outcomes70% success
• TBDExpansion of test panel to include additional neurological indications (e.g., Alzheimer's or Parkinson's)30% success